Connect with us

News

Schwab Declares Common Stock Dividend and Declares Preferred Stock Dividends

gbafNews28

The Board of Directors of The Charles Schwab Corporation at its meeting today declared a regular quarterly cash dividend of $0.18 per common share. The dividend is payable February 26, 2021 to stockholders of record as of the close of business on February 12, 2021.

In addition, the Board of Directors also declared a regular quarterly dividend on the outstanding Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series C, in the amount of $15.00 per share or $0.375 per depositary share, each representing 1/40th interest in a share of Series C Preferred Stock. The dividend is payable March 1, 2021 to stockholders of record at the close of business on February 12, 2021.

The Board of Directors of The Charles Schwab Corporation has also declared a regular quarterly dividend on the outstanding Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series D, in the amount of $14.88 per share or $0.372 per depositary share, each representing 1/40th interest in a share of Series D Preferred Stock. The dividend is payable March 1, 2021 to stockholders of record at the close of business on February 12, 2021.

The Board of Directors of The Charles Schwab Corporation has also declared a regular semi-annual dividend on the outstanding Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series E, in the amount of $2,312.50 per share or $23.125 per depositary share, each representing 1/100th interest in a share of Series E Preferred Stock. The dividend is payable March 1, 2021 to stockholders of record at the close of business on February 12, 2021.

The Board of Directors of The Charles Schwab Corporation has also declared a regular quarterly dividend on the outstanding Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series G, in the amount of $1,343.75 per share or $13.438 per depositary share, each representing 1/100th interest in a share of Series G Preferred Stock. The dividend is payable March 1, 2021 to stockholders of record at the close of business on February 12, 2021.

The Board of Directors of The Charles Schwab Corporation has also declared a regular quarterly dividend on the outstanding Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series H, in the amount of $888.89 per share which covers the period from December 11, 2020 to February 28, 2021. The dividend equals $8.889 per depositary share, each representing 1/100th interest in a share of Series H Preferred Stock. The dividend is payable March 1, 2021 to stockholders of record at the close of business on February 12, 2021.

About Charles Schwab

The Charles Schwab Corporation (NYSE: SCHW) is a leading provider of financial services, with 29.6 million active brokerage accounts, 2.1 million corporate retirement plan participants, 1.5 million banking accounts, and approximately $6.69 trillion in client assets. Through its operating subsidiaries, the company provides a full range of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services to individual investors and independent investment advisors. Its broker-dealer subsidiaries, Charles Schwab & Co., Inc., TD Ameritrade, Inc., and TD Ameritrade Clearing, Inc., (members SIPC, www.sipc.org), and their affiliates offer a complete range of investment services and products including an extensive selection of mutual funds; financial planning and investment advice; retirement plan and equity compensation plan services; referrals to independent, fee-based investment advisors; and custodial, operational and trading support for independent, fee-based investment advisors through Schwab Advisor Services. Its primary banking subsidiary, Charles Schwab Bank, SSB (member FDIC and an Equal Housing Lender), provides banking and lending services and products. More information is available at www.aboutschwab.com.

MEDIA:

Mayura Hooper

Charles Schwab

Phone: 415-667-1525

INVESTORS/ANALYSTS:

Rich Fowler

Charles Schwab

Phone: 415-667-1841

News

AMYRIS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amyris, Inc. – AMRS

gbafNews28

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amyris, Inc. (NasdaqGS: AMRS).  

On November 13, 2018, the Company reported poor financial results for third quarter 2018, with $14.9 million revenue compared to $22.5 million revenue in the prior year period, and attributed the performance to the “volatility of the Vitamin E market.”

On March 19, 2019, the Company disclosed that its 2018 annual report would not be filed timely due to “significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018” and that it “is in the process of completing its evaluation of internal control over financial reporting and may have further deficiencies to report.”

Finally, on  April  11,  2019,  the Company  announced  that  it  was  restating  its fiscal  2018 results  to  reduce  revenue  by  at  least  $12  million  and  increase  net  loss  by  at  least  $7  million, explaining,  among  other  things, that “a  material  error  was  made  related  to  the  estimates  for recognizing  revenue  for  royalty  payments” and that it “expects to report material weaknesses in addition to the material weakness reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017.”

The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws.  Recently, the court in that case denied the Company's motion to dismiss, allowing the case to move forward. 

KSF's investigation is focusing on whether Amyris' officers and/or directors breached their fiduciary duties to Amyris' shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of Amyris shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-amrs/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/amyris-investigation-initiated-by-former-louisiana-attorney-general–kahn-swick–foti-llc-investigates-the-officers-and-directors-of-amyris-inc—amrs-301236794.html

SOURCE Kahn Swick & Foti, LLC

Continue Reading

News

BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. – BMRN

gbafNews28

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN).  

On August 19, 2020, the Company disclosed that it received a Complete Response Letter (“CRL”) from the FDA rejecting its Biologics License Application (“BLA”) for its product, valoctocogene roxaparvovec, and recommending two years of data from the Company's ongoing 270-301 study (Phase 3) and that the Company “complete the Phase 3 Study and submit two-year follow-up safety and efficacy data on all study participants,” thus requiring a lengthier study before approval would be considered.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws, which remains ongoing.

KSF's investigation is focusing on whether BioMarin's officers and/or directors breached their fiduciary duties to BioMarin's shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of BioMarin shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-bmrn/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-investigation-initiated-by-former-louisiana-attorney-general–kahn-swick–foti-llc-investigates-the-officers-and-directors-of-biomarin-pharmaceutical-inc—bmrn-301236793.html

SOURCE Kahn Swick & Foti, LLC

Continue Reading

News

TIVITY HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Tivity Health, Inc. – TVTY

gbafNews28

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Tivity Health, Inc. (NasdaqGS: TVTY).  

On February 19, 2020, the Company announced its financial results for the fourth quarter and year ended December 31, 2019, disclosing that its “Nutrition segment had a disappointing end to 2019” including “a non-cash impairment charge of $377.1 million,” that contributed to a $272.8 million net loss in the fourth quarter, due to complications in the nutrition business since its acquisition of Nutrisystem in March 2019, and also that its Chief Executive Officer had resigned. In September of 2020, the Company announced the resignation of co-founder Daniel G. Tully from its Board of Directors. Then, in October of 2020, it was reported that the Company would be selling Nutrisystem for $575 million, less than half of what Tivity paid to buy it.

The Company and certain of its executives have been sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws, which remains ongoing.

KSF's investigation is focusing on whether Tivity's officers and/or directors breached their fiduciary duties to Tivity's shareholders or otherwise violated state or federal laws. 

If you have information that would assist KSF in its investigation, or have been a long-term holder of Tivity shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tvty/  to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/tivity-health-investigation-initiated-by-former-louisiana-attorney-general–kahn-swick–foti-llc-investigates-the-officers-and-directors-of-tivity-health-inc—tvty-301236792.html

SOURCE Kahn Swick & Foti, LLC

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

Call for Entries

Global Banking and Finance Review Awards Nominations 2021
2021 Awards now open. Click Here to Nominate

Latest Posts

gbafNews28 gbafNews28
News55 mins ago

Industry Leader Joins GyanSys as Chief Business Officer

CARMEL, Ind., Feb. 26, 2021 /PRNewswire/ — GyanSys has hired Anand Aboti as the company's first Chief Business Officer. Aboti...

gbafNews28 gbafNews28
News55 mins ago

TIVITY HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Tivity Health, Inc. – TVTY

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at...

gbafNews28 gbafNews28
News55 mins ago

BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. – BMRN

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at...

gbafNews28 gbafNews28
News55 mins ago

AMYRIS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amyris, Inc. – AMRS

NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ — Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at...

gbafNews28 gbafNews28
News1 hour ago

HKGSEO Provides Free Website SEO Analysis and Consulting Services

HONG KONG SAR – Media OutReach – 22 February 2021 – The COVID-19 epidemic has lasted for nearly a year....

gbafNews28 gbafNews28
News1 hour ago

Media OutReach Expands into China with Strategic Partnership with Xinhua Finance Agency

The newswire continues growing its foothold in Asia by opening its 7th office in the region   HONG KONG SAR...

gbafNews28 gbafNews28
News1 hour ago

Voluntary Announcement: IND Approval Received for A Phase III Clinical Trial of OT-101 in the United States

HONG KONG SAR – Media OutReach – 22 February 2021 – This announcement is made by Ocumension Therapeutics (the “Company“,...

gbafNews28 gbafNews28
News1 hour ago

Citi Plus® Official Launch Ceremony

HONG KONG SAR – Media OutReach – 22 February 2021 Photo 1 Mr Lawrence Lam, Consumer Business Manager of Citibank...

gbafNews28 gbafNews28
News1 hour ago

Hong Kong Productivity Council and Hong Kong Computer Society Sign Pact to Enhance the Adoption of Emerging Technologies in Hong Kong

HONG KONG SAR – Media OutReach – 22 February 2021 – The Hong Kong Productivity Council (HKPC) and the Hong...

gbafNews28 gbafNews28
News1 hour ago

Citibank Officially Launches Citi Plus®

Co-creating With Target Clients to Suit Their Banking and Investment Needs Fostering Financial Education to Level-Up Digital Natives Through Mobile...